Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nephrology | 26 | 2025 | 270 | 7.670 |
Why?
|
Kidney Diseases | 29 | 2025 | 2100 | 6.870 |
Why?
|
Renal Dialysis | 42 | 2024 | 1791 | 4.980 |
Why?
|
Kidney Failure, Chronic | 30 | 2024 | 2504 | 4.390 |
Why?
|
Peritoneal Dialysis | 10 | 2024 | 161 | 3.610 |
Why?
|
Renal Insufficiency, Chronic | 21 | 2024 | 2306 | 3.340 |
Why?
|
Nephrons | 10 | 2023 | 165 | 2.450 |
Why?
|
Kidney | 27 | 2024 | 7072 | 2.180 |
Why?
|
Renal Replacement Therapy | 9 | 2024 | 282 | 2.150 |
Why?
|
Acute Kidney Injury | 22 | 2024 | 1943 | 2.130 |
Why?
|
Health Services Accessibility | 15 | 2024 | 5510 | 1.740 |
Why?
|
Premature Birth | 4 | 2023 | 1830 | 1.210 |
Why?
|
Renal Insufficiency | 6 | 2024 | 810 | 1.160 |
Why?
|
Hypertension | 11 | 2024 | 8616 | 1.120 |
Why?
|
Healthcare Disparities | 6 | 2024 | 3407 | 1.050 |
Why?
|
Hemodialysis, Home | 2 | 2024 | 21 | 1.010 |
Why?
|
Birth Weight | 6 | 2019 | 2122 | 0.970 |
Why?
|
Fetal Development | 3 | 2019 | 777 | 0.950 |
Why?
|
Longevity | 2 | 2023 | 1085 | 0.950 |
Why?
|
Ethics, Research | 4 | 2024 | 178 | 0.930 |
Why?
|
Kidney Transplantation | 13 | 2024 | 4277 | 0.920 |
Why?
|
Medicine, Traditional | 3 | 2012 | 88 | 0.900 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2023 | 24 | 0.880 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2023 | 105 | 0.850 |
Why?
|
Altruism | 1 | 2024 | 211 | 0.810 |
Why?
|
Disasters | 8 | 2024 | 521 | 0.800 |
Why?
|
Glomerular Filtration Rate | 8 | 2023 | 2232 | 0.800 |
Why?
|
Developing Countries | 15 | 2024 | 2914 | 0.770 |
Why?
|
Health Resources | 7 | 2024 | 951 | 0.770 |
Why?
|
Health Care Rationing | 2 | 2021 | 435 | 0.710 |
Why?
|
Humans | 139 | 2025 | 766117 | 0.710 |
Why?
|
Infant, Low Birth Weight | 6 | 2017 | 870 | 0.680 |
Why?
|
Escherichia coli Infections | 1 | 2023 | 519 | 0.660 |
Why?
|
Medicine, African Traditional | 3 | 2005 | 31 | 0.660 |
Why?
|
Africa South of the Sahara | 5 | 2022 | 751 | 0.630 |
Why?
|
Voice | 1 | 2022 | 268 | 0.630 |
Why?
|
Social Responsibility | 2 | 2021 | 382 | 0.610 |
Why?
|
Plant Preparations | 2 | 2012 | 93 | 0.560 |
Why?
|
Conservation of Natural Resources | 1 | 2018 | 209 | 0.500 |
Why?
|
Health Status Disparities | 2 | 2024 | 1878 | 0.490 |
Why?
|
Transients and Migrants | 1 | 2017 | 170 | 0.480 |
Why?
|
Stromal Cells | 1 | 2020 | 1332 | 0.450 |
Why?
|
Delivery of Health Care | 8 | 2024 | 5367 | 0.450 |
Why?
|
Refugees | 2 | 2023 | 615 | 0.450 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1257 | 0.440 |
Why?
|
Infant, Small for Gestational Age | 1 | 2016 | 468 | 0.430 |
Why?
|
Gestational Age | 3 | 2017 | 3616 | 0.430 |
Why?
|
Disease Progression | 7 | 2025 | 13616 | 0.430 |
Why?
|
Epidemics | 1 | 2019 | 515 | 0.420 |
Why?
|
Goals | 1 | 2018 | 717 | 0.410 |
Why?
|
Risk Factors | 19 | 2025 | 74857 | 0.400 |
Why?
|
Pandemics | 10 | 2024 | 8725 | 0.390 |
Why?
|
Health Expenditures | 5 | 2020 | 2389 | 0.390 |
Why?
|
Arteriovenous Shunt, Surgical | 3 | 2024 | 291 | 0.390 |
Why?
|
Health Priorities | 3 | 2024 | 382 | 0.390 |
Why?
|
Living Donors | 3 | 2015 | 647 | 0.370 |
Why?
|
Martial Arts | 1 | 2011 | 29 | 0.360 |
Why?
|
South Africa | 10 | 2024 | 1870 | 0.350 |
Why?
|
Infant, Newborn | 14 | 2024 | 26381 | 0.350 |
Why?
|
Self Medication | 1 | 2011 | 115 | 0.350 |
Why?
|
Quality of Health Care | 3 | 2023 | 4306 | 0.340 |
Why?
|
Acute-Phase Reaction | 2 | 2010 | 91 | 0.340 |
Why?
|
Chloride Channels | 3 | 2000 | 221 | 0.330 |
Why?
|
Disease Management | 2 | 2017 | 2531 | 0.330 |
Why?
|
Aging, Premature | 1 | 2009 | 44 | 0.330 |
Why?
|
Oncostatin M Receptor beta Subunit | 1 | 2009 | 4 | 0.320 |
Why?
|
Oncostatin M | 1 | 2009 | 42 | 0.320 |
Why?
|
Child Welfare | 1 | 2013 | 521 | 0.320 |
Why?
|
Malnutrition | 1 | 2015 | 629 | 0.300 |
Why?
|
Complementary Therapies | 1 | 2012 | 486 | 0.300 |
Why?
|
Africa | 3 | 2024 | 726 | 0.300 |
Why?
|
Biomedical Research | 2 | 2021 | 3458 | 0.290 |
Why?
|
Child | 21 | 2024 | 80573 | 0.290 |
Why?
|
Tendon Injuries | 1 | 2011 | 329 | 0.280 |
Why?
|
Decision Making | 2 | 2020 | 3955 | 0.280 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2019 | 2538 | 0.280 |
Why?
|
Kidney Tubules | 1 | 2009 | 453 | 0.270 |
Why?
|
Endocarditis, Bacterial | 1 | 2011 | 434 | 0.270 |
Why?
|
Switzerland | 2 | 2024 | 322 | 0.260 |
Why?
|
Physicians | 3 | 2023 | 4591 | 0.260 |
Why?
|
Human Growth Hormone | 1 | 2011 | 639 | 0.260 |
Why?
|
Adaptation, Physiological | 1 | 2012 | 1310 | 0.250 |
Why?
|
Internationality | 2 | 2020 | 1007 | 0.240 |
Why?
|
Phosphines | 1 | 2024 | 18 | 0.240 |
Why?
|
Red Cross | 1 | 2024 | 12 | 0.230 |
Why?
|
Glomerulonephritis | 2 | 2024 | 331 | 0.230 |
Why?
|
Malaria | 2 | 2024 | 1246 | 0.220 |
Why?
|
Animals, Newborn | 1 | 2009 | 2677 | 0.220 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2005 | 110 | 0.220 |
Why?
|
Complement Inactivating Agents | 1 | 2023 | 53 | 0.220 |
Why?
|
Androgens | 1 | 2011 | 1278 | 0.210 |
Why?
|
Phytotherapy | 2 | 2003 | 297 | 0.210 |
Why?
|
Uremia | 1 | 2024 | 202 | 0.210 |
Why?
|
Adult | 22 | 2024 | 223139 | 0.200 |
Why?
|
Aloe | 1 | 2002 | 2 | 0.200 |
Why?
|
Poverty | 3 | 2020 | 2714 | 0.200 |
Why?
|
Critical Care | 5 | 2024 | 2714 | 0.180 |
Why?
|
Europe | 4 | 2024 | 3430 | 0.180 |
Why?
|
Pregnancy | 7 | 2024 | 30233 | 0.180 |
Why?
|
Consensus | 3 | 2014 | 3202 | 0.170 |
Why?
|
Dietary Proteins | 2 | 2008 | 960 | 0.170 |
Why?
|
Catastrophic Illness | 1 | 2020 | 60 | 0.170 |
Why?
|
Climate Change | 2 | 2024 | 509 | 0.170 |
Why?
|
Kidney Calculi | 1 | 2004 | 458 | 0.170 |
Why?
|
Carbon | 1 | 2023 | 673 | 0.170 |
Why?
|
Ethics Committees, Research | 1 | 2021 | 196 | 0.170 |
Why?
|
Female | 29 | 2024 | 396233 | 0.160 |
Why?
|
Nephritis, Interstitial | 1 | 2021 | 157 | 0.160 |
Why?
|
Central America | 1 | 2019 | 69 | 0.160 |
Why?
|
Masks | 1 | 2022 | 212 | 0.160 |
Why?
|
Streptococcal Infections | 1 | 2024 | 616 | 0.160 |
Why?
|
Morals | 1 | 2022 | 288 | 0.160 |
Why?
|
Sri Lanka | 1 | 2019 | 93 | 0.160 |
Why?
|
Critical Illness | 4 | 2020 | 2749 | 0.160 |
Why?
|
Policy | 1 | 2023 | 512 | 0.160 |
Why?
|
Relief Work | 2 | 2010 | 131 | 0.160 |
Why?
|
Male | 31 | 2024 | 363935 | 0.160 |
Why?
|
Early Diagnosis | 2 | 2020 | 1186 | 0.160 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3270 | 0.150 |
Why?
|
Kidney Cortex | 1 | 1998 | 167 | 0.150 |
Why?
|
Long-Term Care | 1 | 2023 | 630 | 0.150 |
Why?
|
Organ Size | 2 | 2016 | 2260 | 0.150 |
Why?
|
Thromboembolism | 1 | 2024 | 1001 | 0.150 |
Why?
|
Education | 1 | 2020 | 531 | 0.140 |
Why?
|
Informed Consent | 1 | 2024 | 1010 | 0.140 |
Why?
|
Earthquakes | 2 | 2010 | 192 | 0.140 |
Why?
|
Wounds and Injuries | 3 | 2014 | 2513 | 0.140 |
Why?
|
Health Planning | 1 | 2019 | 233 | 0.140 |
Why?
|
Developed Countries | 4 | 2024 | 452 | 0.140 |
Why?
|
Conflict of Interest | 1 | 2022 | 556 | 0.140 |
Why?
|
Research Support as Topic | 1 | 2021 | 697 | 0.140 |
Why?
|
Hypertension, Renal | 1 | 2017 | 135 | 0.140 |
Why?
|
Blood Pressure | 3 | 2019 | 8532 | 0.140 |
Why?
|
Cystatin C | 2 | 2016 | 272 | 0.140 |
Why?
|
Social Justice | 1 | 2020 | 484 | 0.130 |
Why?
|
Sex Factors | 3 | 2022 | 10614 | 0.130 |
Why?
|
Health Policy | 4 | 2024 | 2700 | 0.130 |
Why?
|
Ethics, Medical | 1 | 2021 | 785 | 0.130 |
Why?
|
Term Birth | 1 | 2016 | 140 | 0.130 |
Why?
|
Malaria, Falciparum | 1 | 2024 | 1073 | 0.120 |
Why?
|
Infant, Premature | 2 | 2017 | 2121 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 787 | 0.120 |
Why?
|
Health Planning Organizations | 1 | 2014 | 13 | 0.120 |
Why?
|
Research Design | 2 | 2024 | 6206 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1850 | 0.120 |
Why?
|
Primary Graft Dysfunction | 1 | 2015 | 112 | 0.110 |
Why?
|
Violence | 1 | 2020 | 931 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 2024 | 1761 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1121 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5531 | 0.110 |
Why?
|
Triage | 1 | 2020 | 994 | 0.110 |
Why?
|
Cardiovascular Diseases | 2 | 2009 | 15647 | 0.110 |
Why?
|
Maternal Age | 1 | 2016 | 804 | 0.110 |
Why?
|
Child, Preschool | 8 | 2024 | 42511 | 0.110 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 7843 | 0.100 |
Why?
|
Maternal Welfare | 1 | 2013 | 113 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2017 | 1404 | 0.100 |
Why?
|
Herb-Drug Interactions | 1 | 2012 | 8 | 0.100 |
Why?
|
Morbidity | 1 | 2018 | 1753 | 0.100 |
Why?
|
Graft Survival | 3 | 2021 | 3904 | 0.100 |
Why?
|
Patient Care Team | 1 | 2023 | 2517 | 0.100 |
Why?
|
Capacity Building | 1 | 2014 | 266 | 0.100 |
Why?
|
Rats | 4 | 2020 | 23717 | 0.100 |
Why?
|
Adolescent | 11 | 2024 | 88819 | 0.100 |
Why?
|
Creatinine | 2 | 2015 | 1916 | 0.100 |
Why?
|
Urea | 2 | 2024 | 449 | 0.090 |
Why?
|
Proteinuria | 2 | 2013 | 606 | 0.090 |
Why?
|
Asia | 2 | 2024 | 630 | 0.090 |
Why?
|
Drug Contamination | 1 | 2012 | 151 | 0.090 |
Why?
|
Renal Artery | 1 | 2012 | 355 | 0.090 |
Why?
|
Delayed Graft Function | 1 | 2011 | 50 | 0.090 |
Why?
|
Renal Colic | 1 | 2011 | 27 | 0.090 |
Why?
|
Crush Syndrome | 1 | 2010 | 8 | 0.090 |
Why?
|
Shc Signaling Adaptor Proteins | 1 | 2009 | 46 | 0.080 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2011 | 123 | 0.080 |
Why?
|
Body Height | 1 | 2016 | 1561 | 0.080 |
Why?
|
Maternal Nutritional Physiological Phenomena | 1 | 2013 | 395 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2024 | 65219 | 0.080 |
Why?
|
Prenatal Care | 1 | 2017 | 1158 | 0.080 |
Why?
|
Rupture | 1 | 2011 | 444 | 0.080 |
Why?
|
Health Care Costs | 2 | 2024 | 3243 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 4565 | 0.080 |
Why?
|
Regional Blood Flow | 1 | 2012 | 1479 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 244 | 0.080 |
Why?
|
Infant | 5 | 2024 | 36427 | 0.080 |
Why?
|
Anticoagulants | 1 | 2024 | 4857 | 0.080 |
Why?
|
Tuberculosis | 1 | 2021 | 2010 | 0.080 |
Why?
|
Calcinosis | 1 | 2017 | 1475 | 0.080 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26290 | 0.080 |
Why?
|
Fetal Growth Retardation | 1 | 2012 | 591 | 0.080 |
Why?
|
Age Factors | 3 | 2012 | 18386 | 0.070 |
Why?
|
alpha 1-Antitrypsin | 1 | 2009 | 168 | 0.070 |
Why?
|
Cystatins | 1 | 2008 | 55 | 0.070 |
Why?
|
Heart Function Tests | 1 | 2009 | 317 | 0.070 |
Why?
|
Health Personnel | 1 | 2022 | 3387 | 0.070 |
Why?
|
Chronic Disease | 3 | 2013 | 9354 | 0.070 |
Why?
|
Acute-Phase Proteins | 1 | 2009 | 252 | 0.070 |
Why?
|
Macrophage Activation | 1 | 2010 | 553 | 0.070 |
Why?
|
Graft Rejection | 2 | 2011 | 4504 | 0.070 |
Why?
|
Receptors, Interleukin-6 | 1 | 2009 | 227 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2021 | 3798 | 0.070 |
Why?
|
Oxidoreductases | 1 | 2009 | 409 | 0.070 |
Why?
|
Primary Health Care | 1 | 2024 | 4736 | 0.070 |
Why?
|
Nephrectomy | 1 | 2012 | 928 | 0.070 |
Why?
|
Cost Sharing | 2 | 2020 | 409 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2911 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2596 | 0.070 |
Why?
|
Retrospective Studies | 9 | 2024 | 81565 | 0.070 |
Why?
|
Calcium | 1 | 1999 | 5770 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2009 | 702 | 0.070 |
Why?
|
Retinoblastoma Protein | 1 | 2009 | 666 | 0.060 |
Why?
|
Research | 1 | 2014 | 1975 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7424 | 0.060 |
Why?
|
Tissue Donors | 1 | 2015 | 2392 | 0.060 |
Why?
|
Signal Transduction | 1 | 2009 | 23605 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 5185 | 0.060 |
Why?
|
Pregnancy Complications | 2 | 2024 | 2970 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13468 | 0.060 |
Why?
|
Fibrinogen | 1 | 2009 | 894 | 0.060 |
Why?
|
Energy Intake | 2 | 2010 | 2141 | 0.060 |
Why?
|
Oceania | 1 | 2024 | 21 | 0.060 |
Why?
|
Young Adult | 4 | 2024 | 59868 | 0.060 |
Why?
|
Costs and Cost Analysis | 2 | 2020 | 1666 | 0.060 |
Why?
|
Aluminum Compounds | 1 | 2024 | 56 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14747 | 0.060 |
Why?
|
Caribbean Region | 1 | 2024 | 193 | 0.060 |
Why?
|
Syria | 1 | 2024 | 88 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2011 | 3796 | 0.060 |
Why?
|
Middle East | 1 | 2024 | 237 | 0.060 |
Why?
|
Russia | 1 | 2024 | 383 | 0.060 |
Why?
|
Enema | 1 | 2004 | 140 | 0.050 |
Why?
|
Sudan | 1 | 2023 | 86 | 0.050 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2009 | 855 | 0.050 |
Why?
|
Latin America | 1 | 2024 | 416 | 0.050 |
Why?
|
Ukraine | 1 | 2023 | 151 | 0.050 |
Why?
|
Ultrasonography | 1 | 2016 | 5988 | 0.050 |
Why?
|
Weight Gain | 1 | 2013 | 2356 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1937 | 0.050 |
Why?
|
Chromones | 1 | 2003 | 148 | 0.050 |
Why?
|
Poisoning | 1 | 2024 | 254 | 0.050 |
Why?
|
Diabetic Nephropathies | 2 | 2008 | 968 | 0.050 |
Why?
|
Liver Failure | 1 | 2005 | 252 | 0.050 |
Why?
|
Peritoneum | 1 | 2023 | 226 | 0.050 |
Why?
|
Ghana | 1 | 2023 | 333 | 0.050 |
Why?
|
Plants, Medicinal | 1 | 2003 | 165 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 2 | 2012 | 8113 | 0.050 |
Why?
|
Curriculum | 1 | 2016 | 3784 | 0.050 |
Why?
|
Comorbidity | 2 | 2009 | 10579 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 2000 | 1056 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2009 | 2144 | 0.050 |
Why?
|
Child Development | 1 | 2013 | 2327 | 0.050 |
Why?
|
Catheters, Indwelling | 1 | 2023 | 436 | 0.050 |
Why?
|
Tea | 1 | 2003 | 289 | 0.050 |
Why?
|
Australasia | 1 | 2020 | 20 | 0.050 |
Why?
|
Orthopedic Procedures | 1 | 2011 | 1279 | 0.050 |
Why?
|
North America | 1 | 2024 | 1287 | 0.040 |
Why?
|
Ethical Analysis | 1 | 2020 | 41 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2024 | 551 | 0.040 |
Why?
|
Middle Aged | 11 | 2024 | 223083 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18321 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2002 | 277 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18076 | 0.040 |
Why?
|
Animals | 8 | 2020 | 168800 | 0.040 |
Why?
|
Isoniazid | 1 | 2021 | 279 | 0.040 |
Why?
|
Withholding Treatment | 1 | 2024 | 619 | 0.040 |
Why?
|
RNA, Catalytic | 1 | 1999 | 52 | 0.040 |
Why?
|
Transportation of Patients | 1 | 2020 | 177 | 0.040 |
Why?
|
Epidemiologic Methods | 1 | 2004 | 1325 | 0.040 |
Why?
|
Waiting Lists | 1 | 2024 | 779 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9445 | 0.040 |
Why?
|
Administrative Personnel | 1 | 2020 | 186 | 0.040 |
Why?
|
Prevalence | 2 | 2023 | 15827 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15808 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2010 | 2894 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2009 | 3227 | 0.040 |
Why?
|
Electrolytes | 1 | 1999 | 279 | 0.040 |
Why?
|
Kidney Tubules, Proximal | 1 | 2000 | 386 | 0.040 |
Why?
|
Granuloma | 1 | 2021 | 329 | 0.040 |
Why?
|
Gene Expression | 2 | 2009 | 7582 | 0.040 |
Why?
|
Fetus | 1 | 2006 | 1878 | 0.040 |
Why?
|
Aged | 5 | 2024 | 171219 | 0.040 |
Why?
|
Haiti | 2 | 2010 | 553 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2024 | 7871 | 0.040 |
Why?
|
Cause of Death | 1 | 2009 | 3715 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 3692 | 0.040 |
Why?
|
Glucosides | 1 | 2003 | 532 | 0.040 |
Why?
|
Body Mass Index | 2 | 2013 | 13046 | 0.040 |
Why?
|
Urogenital Abnormalities | 1 | 2020 | 255 | 0.040 |
Why?
|
Syndrome | 1 | 2024 | 3270 | 0.040 |
Why?
|
Health Occupations | 1 | 2019 | 226 | 0.040 |
Why?
|
Diet | 2 | 2009 | 8087 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1740 | 0.030 |
Why?
|
Constipation | 1 | 2002 | 568 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 1999 | 602 | 0.030 |
Why?
|
Biopsy | 1 | 2009 | 6768 | 0.030 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2020 | 433 | 0.030 |
Why?
|
Patient Advocacy | 1 | 2019 | 361 | 0.030 |
Why?
|
Myocardium | 1 | 2009 | 4766 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 9527 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 24276 | 0.030 |
Why?
|
Echocardiography | 1 | 2009 | 5041 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2009 | 4910 | 0.030 |
Why?
|
Liver Diseases | 1 | 2004 | 1304 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1413 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2009 | 18967 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2120 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 1999 | 736 | 0.030 |
Why?
|
Stroke Volume | 1 | 2009 | 5595 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1998 | 1885 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3719 | 0.030 |
Why?
|
Base Sequence | 3 | 2000 | 12405 | 0.030 |
Why?
|
Competency-Based Education | 1 | 2016 | 226 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2016 | 210 | 0.030 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1999 | 1119 | 0.030 |
Why?
|
Acute Disease | 1 | 2024 | 7237 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 2021 | 1380 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5300 | 0.030 |
Why?
|
RNA, Messenger | 3 | 2011 | 12775 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10737 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2017 | 811 | 0.020 |
Why?
|
Phenylephrine | 1 | 2012 | 291 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 1331 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2016 | 499 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2304 | 0.020 |
Why?
|
Prospective Studies | 3 | 2024 | 54812 | 0.020 |
Why?
|
Maps as Topic | 1 | 2010 | 18 | 0.020 |
Why?
|
Neopterin | 1 | 2010 | 57 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15882 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2009 | 20137 | 0.020 |
Why?
|
Choline | 1 | 2012 | 511 | 0.020 |
Why?
|
Kidney Glomerulus | 2 | 2006 | 567 | 0.020 |
Why?
|
Aging | 1 | 2009 | 8723 | 0.020 |
Why?
|
Serum Amyloid A Protein | 1 | 2010 | 127 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 829 | 0.020 |
Why?
|
Hospitals | 1 | 2024 | 3887 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2000 | 17597 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3214 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41684 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 13085 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2002 | 4423 | 0.020 |
Why?
|
Chile | 1 | 2010 | 258 | 0.020 |
Why?
|
Calorimetry, Indirect | 1 | 2010 | 176 | 0.020 |
Why?
|
Models, Genetic | 1 | 1999 | 3448 | 0.020 |
Why?
|
Drug Discovery | 1 | 2017 | 1065 | 0.020 |
Why?
|
Body Weight | 1 | 1999 | 4626 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10087 | 0.020 |
Why?
|
Quality Improvement | 1 | 2024 | 3849 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8347 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3955 | 0.020 |
Why?
|
HIV Infections | 2 | 2005 | 17535 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4213 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10380 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 1999 | 9540 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2005 | 5889 | 0.020 |
Why?
|
Survival Rate | 2 | 2011 | 12827 | 0.020 |
Why?
|
Apoptosis | 1 | 2002 | 9508 | 0.020 |
Why?
|
Oligosaccharides | 1 | 2008 | 406 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1447 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2008 | 684 | 0.020 |
Why?
|
Anthropometry | 1 | 2010 | 1339 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11035 | 0.010 |
Why?
|
Genotype | 1 | 1999 | 13028 | 0.010 |
Why?
|
Rest | 1 | 2010 | 940 | 0.010 |
Why?
|
Education, Medical | 1 | 2016 | 1744 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2012 | 2142 | 0.010 |
Why?
|
International Cooperation | 1 | 2010 | 1433 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2419 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36548 | 0.010 |
Why?
|
Eating | 1 | 2010 | 1538 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21513 | 0.010 |
Why?
|
Reference Values | 1 | 2010 | 4909 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 4860 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 2002 | 147 | 0.010 |
Why?
|
Phenotype | 1 | 1999 | 16716 | 0.010 |
Why?
|
Cytoprotection | 1 | 2002 | 200 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8038 | 0.010 |
Why?
|
Biological Factors | 1 | 2002 | 155 | 0.010 |
Why?
|
LLC-PK1 Cells | 1 | 2000 | 125 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 2002 | 520 | 0.010 |
Why?
|
Body Composition | 1 | 2010 | 2441 | 0.010 |
Why?
|
Prognosis | 2 | 2011 | 29912 | 0.010 |
Why?
|
Clinical Competence | 1 | 2016 | 4859 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 1999 | 61 | 0.010 |
Why?
|
Vomiting | 1 | 2003 | 647 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2011 | 39243 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2003 | 1527 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15403 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 1999 | 153 | 0.010 |
Why?
|
Xenopus | 1 | 2000 | 709 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2010 | 3853 | 0.010 |
Why?
|
Molecular Structure | 1 | 2003 | 1881 | 0.010 |
Why?
|
Enalapril | 1 | 1999 | 317 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2000 | 1984 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2002 | 1205 | 0.010 |
Why?
|
Growth Substances | 1 | 1999 | 758 | 0.010 |
Why?
|
United States | 1 | 2024 | 72920 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2003 | 2195 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1999 | 1886 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 4163 | 0.010 |
Why?
|
DNA Primers | 1 | 1999 | 2824 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2002 | 1370 | 0.010 |
Why?
|
Biphenyl Compounds | 1 | 1999 | 1019 | 0.010 |
Why?
|
Benzimidazoles | 1 | 1999 | 862 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40108 | 0.010 |
Why?
|
Tetrazoles | 1 | 1999 | 918 | 0.010 |
Why?
|
Blood Glucose | 1 | 2008 | 6421 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2003 | 3678 | 0.010 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 1999 | 1060 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 1513 | 0.010 |
Why?
|
Mice | 1 | 1999 | 81839 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2010 | 22228 | 0.010 |
Why?
|
Cell Survival | 1 | 2002 | 5747 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2002 | 2946 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3722 | 0.010 |
Why?
|
Swine | 1 | 2000 | 5986 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2000 | 13400 | 0.000 |
Why?
|
Mitochondria | 1 | 2002 | 3672 | 0.000 |
Why?
|
Macrophages | 1 | 1999 | 5776 | 0.000 |
Why?
|
Cytokines | 1 | 1999 | 7426 | 0.000 |
Why?
|